EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death

Mathias Jachs iD, Tânia Carvalho iD, Benedikt Simbrunner iD, Georg Semmler iD, Lukas Hartl iD, Lorenz Balcar iD, Benedikt Silvester Hofer iD, Paul Thöne iD, Nina Dominik iD, Georg Kramer iD, Christian Sebesta iD, Michael Schwarz und 6 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Mathias Jachs und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Indocyanine Green, Acute-On-Chronic Liver Failure, Liver Cirrhosis, Hypertension, Portal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds Zukunft Österreich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Indocyanine green (ICG) clearance, determined by venous sampling, has shown promising results in the diagnosis of clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) and prognostication in decompensated ACLD (decompensated cirrhosis). Data on ICG clearance measurement by pulse dye densitometry (PDD) via finger clip are comparatively scarce.

Aims

To evaluate the diagnostic (CSPH) and prognostic utility of ICG clearance throughout ACLD stages.

Methods

ACLD (liver stiffness ≥ 10 kPa) patients undergoing same‐day hepatic venous pressure gradient (HVPG) measurement and ICG clearance assessment via PDD in 2017–2022 were recruited from the prospective Vienna Cirrhosis Study (VICIS, NCT03267615).

Results

Two hundred and sixty‐one ACLD patients (cACLD: n = 115, decompensated cirrhosis: n = 146) were included. Among cACLD patients (CSPH: 62.4%), ICG retention 15 min (ICG‐R15) correlated moderately with HVPG (Spearman's rho:0.458; p < 0.001) and yielded a suboptimal diagnostic accuracy for CSPH (AUROC: 0.687 [95% CI: 0.585–0.789]). ICG‐R15 showed a strong correlation with the model for end‐stage liver disease score (rho: 0.701; p < 0.001) and correlated with biomarkers of endothelial dysfunction (von Willebrand factor), systemic inflammation (C‐reactive protein, procalcitonin, interleukin 6) and extracellular matrix remodelling (enhanced liver fibrosis test). In decompensated cirrhosis, ICG‐R15 additionally correlated with mean arterial pressure, serum sodium and renin levels. ICG‐R15 predicted decompensation (subdistribution hazard ratio [SHR]: 1.042 [95% CI: 1.008–1.077] per %; p = 0.014) in cACLD and independently predicted ACLF/liver‐related mortality in decompensated cirrhosis (adjusted SHR: 1.062 [95% CI: 1.025–1.100] per %; p < 0.001).

Conclusions

ICG‐R15 by PDD correlates with portal hypertension and systemic inflammation/circulatory dysfunction as key disease‐driving mechanisms in ACLD. While showing insufficient discrimination for CSPH, ICG‐R15 independently predicted ACLF/liver‐related mortality in decompensated cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Indocyanine GreenAcute-On-Chronic Liver FailureLiver CirrhosisHypertension, PortalColoring AgentsHumansMaleFemaleMiddle AgedBiomarkersProspective StudiesAgedPrognosisPredictive Value of TestsAdult

Stichwörter der Autor:innen

circulatory dysfunctioncirrhosishepatic venous pressure gradientpulse dye densitometrysystemic inflammation

Substanzen

Indocyanine GreenBiomarkersColoring Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria.
  • Gastroenterology Department, Unidade Local de Saúde de Braga, Braga, Portugal.
  • Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.

ORCID-Profile: Mathias Jachs, Tânia Carvalho, Benedikt Simbrunner, Georg Semmler, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Paul Thöne, Nina Dominik, Georg Kramer, Christian Sebesta, David Bauer, Matthias Pinter, Thomas Reiberger, Mattias Mandorfer

Förderung

  • Fonds Zukunft Österreich

Zitieren

APA

Jachs, M., Carvalho, T., Simbrunner, B., Semmler, G., Hartl, L., Balcar, L., Hofer, B. S., Thöne, P., Dominik, N., Kramer, G., Sebesta, C., Schwarz, M., Bauer, D., Stättermayer, A. F., Pinter, M., Trauner, M., Reiberger, T., & Mandorfer, M. (2026). Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70447

Vancouver

Jachs M, Carvalho T, Simbrunner B, Semmler G, Hartl L, Balcar L, et al. Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70447

BibTeX
@article{Jachs2026,
  author = {Jachs, Mathias and Carvalho, Tânia and Simbrunner, Benedikt and Semmler, Georg and Hartl, Lukas and Balcar, Lorenz and Hofer, Benedikt Silvester and Thöne, Paul and Dominik, Nina and Kramer, Georg and Sebesta, Christian and Schwarz, Michael and Bauer, David and Stättermayer, Albert F and Pinter, Matthias and Trauner, Michael and Reiberger, Thomas and Mandorfer, Mattias},
  title = {Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70447}
}
Kostenlos starten →